Shifting the balance: soluble ADAM10 as a potential treatment for Alzheimer's disease
Authors:
Open Access
- 17 May 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 15, 1171123
Abstract
Introduction: Accumulation of amyloid β in the brain is regarded as a key initiator of Alzheimer's disease pathology. Processing of the amyloid precursor protein (APP) in the amyloidogenic pathway yields neurotoxic amyloid β species. In the non-amyloidogenic pathway, APP is processed by membrane-bound ADAM10, the main α-secretase in the nervous system. Here we present a new enzymatic approach for the potential treatment of Alzheimer's disease using a soluble form of ADAM10.Methods: The ability of the soluble ADAM10 to shed overexpressed and endogenous APP was determined with an ADAM10 knockout cell line and a human neuroblastoma cell line, respectively. We further examined its effect on amyloid β aggregation by thioflavin T fluorescence, HPLC, and confocal microscopy. Using N-terminal and C-terminal enrichment proteomic approaches, we identified soluble ADAM10 substrates. Finally, a truncated soluble ADAM10, based on the catalytic domain, was expressed in Escherichia coli for the first time, and its activity was evaluated.Results: The soluble enzyme hydrolyzes APP and releases the neuroprotective soluble APPα when exogenously added to cell cultures. The soluble ADAM10 inhibits the formation and aggregation of characteristic amyloid β extracellular neuronal aggregates. The proteomic investigation identified new and verified known substrates, such as VGF and N-cadherin, respectively. The truncated variant also exhibited α-secretase capacity as shown with a specific ADAM10 fluorescent substrate in addition to shedding overexpressed and endogenous APP.Discussion: Our in vitro study demonstrates that exogenous treatment with a soluble variant of ADAM10 would shift the balance toward the non-amyloidogenic pathway, thus utilizing its natural neuroprotective effect and inhibiting the main neurotoxic amyloid β species. The potential of such a treatment for Alzheimer's disease needs to be further evaluated in vivo.Keywords
This publication has 129 references indexed in Scilit:
- The Neuroendocrine Protein 7B2 Suppresses the Aggregation of Neurodegenerative Disease-related ProteinsJournal of Biological Chemistry, 2013
- Soluble amyloid precursor protein-α modulates β-secretase activity and amyloid-β generationNature Communications, 2012
- Protocadherin-12 Cleavage Is a Regulated Process Mediated by ADAM10 ProteinJournal of Biological Chemistry, 2011
- ADAM10 is the physiologically relevant, constitutive α‐secretase of the amyloid precursor protein in primary neuronsThe EMBO Journal, 2010
- Structural conversion of neurotoxic amyloid-β1–42 oligomers to fibrilsNature Structural & Molecular Biology, 2010
- A guided tour of the Trans‐Proteomic PipelineProteomics, 2010
- Alcadein Cleavages by Amyloid β-Precursor Protein (APP) α- and γ-Secretases Generate Small Peptides, p3-Alcs, Indicating Alzheimer Disease-related γ-Secretase DysfunctionJournal of Biological Chemistry, 2009
- Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10Biochemical Journal, 2009
- Empirical Statistical Model To Estimate the Accuracy of Peptide Identifications Made by MS/MS and Database SearchAnalytical Chemistry, 2002
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991